Search results for "KINASE"

showing 10 items of 2635 documents

Myotonic dystrophy: candidate small molecule therapeutics

2017

Myotonic dystrophy type 1 (DM1) is a rare multisystemic neuromuscular disorder caused by expansion of CTG trinucleotide repeats in the noncoding region of the DMPK gene. Mutant DMPK transcripts are toxic and alter gene expression at several levels. Chiefly, the secondary structure formed by CUGs has a strong propensity to capture and retain proteins, like those of the muscleblind-like (MBNL) family. Sequestered MBNL proteins cannot then fulfill their normal functions. Many therapeutic approaches have been explored to reverse these pathological consequences. Here, we review the myriad of small molecules that have been proposed for DM1, including examples obtained from computational rational …

musculoskeletal diseases0301 basic medicineTherapeutic gene modulationcongenital hereditary and neonatal diseases and abnormalitiesMutantComputational biologyBiologyMyotonic dystrophyMyotonin-Protein Kinase03 medical and health sciences0302 clinical medicineTrinucleotide RepeatsDrug DiscoveryGene expressionmedicineAnimalsHumansMyotonic DystrophyGenePharmacologyRegulation of gene expressionGeneticsDrug RepositioningRational designmedicine.diseaseSmall moleculeHigh-Throughput Screening Assays030104 developmental biologyGene Expression RegulationDrug Design030217 neurology & neurosurgeryDrug Discovery Today
researchProduct

Expanded CCUG repeat RNA expression in Drosophila heart and muscle trigger Myotonic Dystrophy type 1-like phenotypes and activate autophagocytosis ge…

2016

AbstractMyotonic dystrophies (DM1–2) are neuromuscular genetic disorders caused by the pathological expansion of untranslated microsatellites. DM1 and DM2, are caused by expanded CTG repeats in the 3′UTR of the DMPK gene and CCTG repeats in the first intron of the CNBP gene, respectively. Mutant RNAs containing expanded repeats are retained in the cell nucleus, where they sequester nuclear factors and cause alterations in RNA metabolism. However, for unknown reasons, DM1 is more severe than DM2. To study the differences and similarities in the pathogenesis of DM1 and DM2, we generated model flies by expressing pure expanded CUG ([250]×) or CCUG ([1100]×) repeats, respectively, and compared …

musculoskeletal diseases0301 basic medicinecongenital hereditary and neonatal diseases and abnormalitiesRNA SplicingScienceGene ExpressionBiologyMyotonic dystrophyMyotonin-Protein KinaseArticle03 medical and health sciencesGene expressionAutophagymedicineAnimalsMyotonic DystrophyMuscle SkeletalGeneDNA Repeat ExpansionMultidisciplinaryMyocardiumQRIntronRNAArrhythmias CardiacDNA Repeat Expansionmedicine.diseaseMolecular biologyDisease Models AnimalCell nucleus030104 developmental biologymedicine.anatomical_structureRNA splicingMedicineDrosophilaLocomotionScientific Reports
researchProduct

Sense and Antisense DMPK RNA Foci Accumulate in DM1 Tissues during Development.

2015

International audience; Myotonic dystrophy type 1 (DM1) is caused by an unstable expanded CTG repeat located within the DMPK gene 3'UTR. The nature, severity and age at onset of DM1 symptoms are very variable in patients. Different forms of the disease are described, among which the congenital form (CDM) is the most severe. Molecular mechanisms of DM1 are well characterized for the adult form and involve accumulation of mutant DMPK RNA forming foci in the nucleus. These RNA foci sequester proteins from the MBNL family and deregulate CELF proteins. These proteins are involved in many cellular mechanisms such as alternative splicing, transcriptional, translational and post-translational regul…

musculoskeletal diseasesCCAAT-Enhancer-Binding Protein-deltacongenital hereditary and neonatal diseases and abnormalities[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiologylcsh:MedicineMice Transgenic[SDV.GEN.GH] Life Sciences [q-bio]/Genetics/Human genetics[SDV.BBM.BM] Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologyMyotonin-Protein KinaseMice[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]AnimalsHumansMyotonic DystrophyRNA AntisenseRNA Messengerlcsh:ScienceMuscle SkeletalCell NucleusMyocardiumlcsh:R[SDV.NEU.NB] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/NeurobiologyBrainGene Expression Regulation DevelopmentalRNA-Binding Proteins[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologyEmbryo MammalianAlternative SplicingDisease Models Animal[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human geneticsAnimals Newborn[SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]lcsh:QTrinucleotide Repeat ExpansionSignal TransductionResearch ArticlePloS one
researchProduct

Acute (0-2h) and delayed (2-8D) effects of exercise-induced muscle damage and soreness on elbow target movements.

2011

The aim was to examine the acute and delayed effects of exercise-induced muscle damage and soreness on elbow target movements (TM) performance and control. Ten males performed an exercise of 50 maximal eccentric elbow actions. TMs were performed at three movement ranges. Maximal forces, active stretch reflex and TM were tested, and muscle soreness, creatine kinase and elbow joint stiffness were determined acute (after and 2 h) and delayed (2, 4, 6, 8d) postexercise. Both the long lasting muscle soreness and force drop were observed after the exercise. Joint stiffness was increased at 2 h postexercise. The highest deterioration in flexion-TM performance was found at the time (2 h) and at the…

musculoskeletal diseasesMaleReflex Stretchmedicine.medical_specialtyElbowPainPhysical Therapy Sports Therapy and RehabilitationElectromyographyPhysiology (medical)Internal medicineIsometric ContractionmedicineElbowEccentricHumansStretch reflexExercise physiologyMuscle SkeletalCreatine KinaseExercisemedicine.diagnostic_testbusiness.industryElectromyographyMotor controlAnatomymusculoskeletal systembody regionsmedicine.anatomical_structureJoint stiffnessMuscle FatigueReflexCardiologyNeurology (clinical)medicine.symptombusinessElbow InjuriesMotor control
researchProduct

Myopathy with hexagonally cross-linked crystalloid inclusions: delineation of a clinico-pathological entity.

2010

A novel myopathy characterized by hexagonally cross-linked tubular arrays has been reported in five patients. We studied the clinical and histopathological features of five additional unrelated patients with this myopathy. Patients experienced exercise intolerance with exercise-induced myalgia and weakness, without rhabdomyolysis. One patient additionally presented mild permanent pelvic girdle muscle weakness. Age at onset varied between 13 and 56 years. The inclusions were eosinophilic on H and E, bright red with modified Gomori’s trichrome stains, present in type 2 fibers, and revealed immunoreactivity selectively for a caveolin-3-antibody. Ultrastructurally, the inclusions showed a highl…

myalgiaAdultMaleWeaknessPathologymedicine.medical_specialtyAdolescentCaveolin 3Blotting WesternExercise intoleranceNemaline myopathyMuscular DiseasesTrichromemedicineHumansAge of OnsetMyopathyMuscle SkeletalCreatine KinaseExerciseGenetics (clinical)Muscle Weaknessbusiness.industryMuscle weaknessMiddle Agedmedicine.diseaseImmunohistochemistryPhenotypeNeurologyPediatrics Perinatology and Child HealthFemaleNeurology (clinical)medicine.symptombusinessRhabdomyolysisNeuromuscular disorders : NMD
researchProduct

Effects of Coenzyme Q10 on Statin-Induced Myopathy

2015

Abstract Objective To evaluate the efficacy of coenzyme Q10 (CoQ10) supplementation on statin-induced myopathy. Participants and Methods We searched the MEDLINE, Cochrane Library, Scopus, and EMBASE databases (November 1, 1987, to May 1, 2014) to identify randomized controlled trials investigating the impact of CoQ10 on muscle pain and plasma creatine kinase (CK) activity as 2 measures of statin-induced myalgia. Two independent reviewers extracted data on study characteristics, methods, and outcomes. Results We included 6 studies with 302 patients receiving statin therapy: 5 studies with 226 participants evaluated the effect of CoQ10 supplementation on plasma CK activity, and 5 studies (4 u…

myalgiaCoenzyme Q10medicine.medical_specialtybiologybusiness.industryGeneral MedicineCochrane Librarylaw.inventionchemistry.chemical_compoundRandomized controlled trialchemistrylawStrictly standardized mean differenceInternal medicineMeta-analysisbiology.proteinPhysical therapyMedicineCreatine kinasemedicine.symptombusinessMyopathyMayo Clinic Proceedings
researchProduct

Eight new mutations and the expanding phenotype variability in muscular dystrophy caused by ANO5.

2012

Objective: Description of 8 new ANO5 mutations and significant expansion of the clinical phenotype spectrum associated with previously known and unknown mutations to improve diagnostic accuracy. Methods: DNA samples of 101 patients in 95 kindreds at our quaternary referral center in Finland, who had undetermined limb-girdle muscular dystrophy (LGMD), calf distal myopathy, or creatine kinase (CK) elevations of more than 2,000 IU/L, were selected for ANO5 genetic evaluation, and the clinical findings of patients with mutations were retrospectively analyzed. Results: A total of 25 patients with muscular dystrophy caused by 11 different recessive mutations in the ANO5 gene were identified. The …

myalgiaMalePathologymedicine.disease_causeCohort Studies0302 clinical medicineMedicineMuscular dystrophyAge of OnsetCreatine KinaseFinland0303 health sciencesMutationMuscle WeaknessbiologyMiddle AgedPhenotypeMagnetic Resonance Imaging3. Good healthPhenotypeFemalemedicine.symptomAdultmedicine.medical_specialtyWeaknessGenotypeBlotting WesternAnoctaminsGenes RecessiveAsymptomatic03 medical and health sciencesChloride ChannelsHumansGenetic TestingMyopathyMuscle Skeletal030304 developmental biologyAgedbusiness.industryGenetic VariationReproducibility of ResultsDNAmedicine.diseaseMuscular Dystrophies Limb-GirdleMutationbiology.proteinCreatine kinaseNeurology (clinical)business030217 neurology & neurosurgeryNeurology
researchProduct

Hypokalemic rhabdomyolysis associated with Bartter's syndrome.

1983

Severe potassium deficiency is an uncommon cause of rhabdomyolysis. We recently treated a 45-year-old patient with myalgia, serious generalized weakness, increased serum creatine kinase and myoglobin level as well as excessive hypokalemia. Histological examination of deltoid muscle biopsy showed rhabdomyolysis. After complete recovery of muscle damage by potassium substitution Bartter's syndrome proved to be the cause of initial and persistent hypokalemia.

myalgiaMalemedicine.medical_specialtyendocrine system diseasesHypokalemiaurologic and male genital diseasesGastroenterologyNecrosisInternal medicineDeltoid muscleDrug DiscoveryBiopsyHyperaldosteronismmedicineHumansCreatine KinaseGenetics (clinical)Histological examinationmedicine.diagnostic_testbusiness.industryMyoglobinMusclesMyoglobinuriaBartter SyndromeGeneral MedicineMiddle Agedmedicine.diseaseHypokalemiaBartter's syndromeAnesthesiaPotassiumMolecular MedicinePotassium deficiencymedicine.symptombusinessRhabdomyolysisKlinische Wochenschrift
researchProduct

2015

Aim Our study aimed to investigate changes of different markers for routine assessment of fatigue and recovery in response to high-intensity interval training (HIIT). Methods 22 well-trained male and female team sport athletes (age, 23.0 ± 2.7 years; VO2max, 57.6 ± 8.6 mL·min·kg−1) participated in a six-day running-based HIIT-microcycle with a total of eleven HIIT sessions. Repeated sprint ability (RSA; criterion measure of fatigue and recovery), countermovement jump (CMJ) height, jump efficiency in a multiple rebound jump test (MRJ), 20-m sprint performance, muscle contractile properties, serum concentrations of creatinkinase (CK), c-reactive protein (CRP) and urea as well as perceived mus…

myalgiamedicine.medical_specialtyMultidisciplinarybiologyTeam sportMuscle fatiguebusiness.industryInterval trainingConfidence intervalSprintbiology.proteinPhysical therapymedicineCreatine kinasemedicine.symptombusinessHigh-intensity interval trainingPLOS ONE
researchProduct

Targeting GSK3 and Associated Signaling Pathways Involved in Cancer

2020

Glycogen synthase kinase 3 (GSK-3) is a serine/threonine (S/T) protein kinase. Although GSK-3 originally was identified to have functions in regulation of glycogen synthase, it was subsequently determined to have roles in multiple normal biochemical processes as well as various disease conditions. GSK-3 is sometimes referred to as a moonlighting protein due to the multiple substrates and processes which it controls. Frequently, when GSK-3 phosphorylates proteins, they are targeted for degradation. GSK-3 is often considered a component of the PI3K/PTEN/AKT/GSK-3/mTORC1 pathway as GSK-3 is frequently phosphorylated by AKT which regulates its inactivation. AKT is often active in human cancer a…

natural productnatural productsmTORC1Reviewmacromolecular substancesProtein Serine-Threonine KinasesGlycogen Synthase Kinase 3GSK-3NeoplasmsHumansPhosphorylationProtein kinase AGlycogen synthaselcsh:QH301-705.5Protein kinase BWnt Signaling PathwayPI3K/AKT/mTOR pathwayGSK-3drug resistancenaturalproductsbiologyChemistryWnt signaling pathwayGeneral Medicinetargeted therapyCell biologylcsh:Biology (General)biology.proteinSignal transductionProto-Oncogene Proteins c-akt
researchProduct